X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (395) 395
humans (392) 392
animals (285) 285
cancer (220) 220
oncology (185) 185
mice (164) 164
pharmacology & pharmacy (164) 164
enhanced antitumor-activity (163) 163
antitumor-activity (153) 153
cell line, tumor (144) 144
tumors (117) 117
female (116) 116
drug delivery systems (112) 112
immunotherapy (97) 97
nanoparticles (96) 96
chemotherapy (93) 93
care and treatment (82) 82
in-vivo (81) 81
medicine, research & experimental (79) 79
male (78) 78
research (75) 75
health aspects (69) 69
biotechnology & applied microbiology (68) 68
drugs (66) 66
immunology (66) 66
in-vitro (65) 65
biochemistry & molecular biology (64) 64
article (62) 62
drug-delivery (60) 60
gene therapy (60) 60
review (60) 60
drug delivery (59) 59
mice, nude (58) 58
convection-enhanced delivery (56) 56
enhanced permeability (56) 56
medicine (56) 56
antineoplastic agents - administration & dosage (55) 55
cancer therapies (55) 55
neoplasms - therapy (55) 55
xenograft model antitumor assays (55) 55
antineoplastic agents - pharmacology (53) 53
apoptosis (52) 52
therapy (52) 52
adoptive immunotherapy (51) 51
cytotoxicity (51) 51
nanoscience & nanotechnology (51) 51
neoplasms - drug therapy (51) 51
t cells (51) 51
receptors, antigen, t-cell - genetics (50) 50
lymphocytes (49) 49
chemistry, multidisciplinary (47) 47
t-lymphocytes - immunology (47) 47
breast-cancer (45) 45
antineoplastic agents - therapeutic use (44) 44
expression (44) 44
vehicles (40) 40
mice, inbred balb c (39) 39
micelles (39) 39
antitumor activity (38) 38
cell biology (38) 38
analysis (37) 37
brain neoplasms - drug therapy (37) 37
clinical trials as topic (36) 36
doxorubicin (36) 36
neoplasms - immunology (36) 36
receptors, antigen, t-cell - immunology (36) 36
clinical trials (35) 35
liposomes (35) 35
cancer regression (34) 34
drug therapy (34) 34
genetic aspects (34) 34
rats (34) 34
solid tumors (34) 34
treatment outcome (34) 34
genetics & heredity (33) 33
antigens (32) 32
antineoplastic agents (32) 32
breast cancer (32) 32
metastasis (32) 32
metastatic melanoma (32) 32
toxicity (32) 32
angiogenesis (31) 31
drug delivery systems - methods (31) 31
usage (31) 31
antineoplastic agents - chemistry (30) 30
cell proliferation - drug effects (30) 30
cell survival - drug effects (30) 30
gene expression (30) 30
permeability (30) 30
pharmacology (30) 30
adoptive transfer (29) 29
antineoplastic agents - pharmacokinetics (29) 29
cells (29) 29
antigens, neoplasm - immunology (28) 28
apoptosis - drug effects (28) 28
dose-response relationship, drug (28) 28
enhanced survival (28) 28
genetic engineering (28) 28
glioma (28) 28
physiological aspects (28) 28
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS Medicine, ISSN 1549-1277, 01/2008, Volume 5, Issue 1, pp. 0139 - 0151
Background There is much discussion in the cancer drug development community about how to incorporate molecular tools into early-stage clinical trials to... 
TYROSINE KINASE INHIBITORS | BREAST-CANCER | MALIGNANT GLIOMA | MAMMALIAN TARGET | CELLS | MEDICINE, GENERAL & INTERNAL | ENHANCED SENSITIVITY | PATHWAY | PROTEIN-KINASE | MTOR INHIBITORS | INSULIN-RECEPTOR SUBSTRATE-1 | Glioblastoma - enzymology | Humans | Middle Aged | PTEN Phosphohydrolase - physiology | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Male | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Neoplasm Recurrence, Local - surgery | Brain Neoplasms - surgery | Glioblastoma - genetics | Antineoplastic Agents - adverse effects | Adult | Female | Neoadjuvant Therapy | Antineoplastic Agents - pharmacology | Proto-Oncogene Proteins c-akt - metabolism | Sirolimus - adverse effects | PTEN Phosphohydrolase - genetics | Brain Neoplasms - enzymology | PTEN Phosphohydrolase - deficiency | Sirolimus - therapeutic use | Brain Neoplasms - genetics | Combined Modality Therapy | Brain Neoplasms - drug therapy | Sirolimus - pharmacology | Cell Division - drug effects | Disease Progression | Glioblastoma - surgery | Feedback, Physiological | Signal Transduction - drug effects | Protein Kinase Inhibitors - therapeutic use | Ribosomal Protein S6 - metabolism | Protein Kinases - physiology | Aged | Protein Kinase Inhibitors - pharmacology | TOR Serine-Threonine Kinases | Glioblastoma - drug therapy | Index Medicus | Pathology | Chemotherapy | Genetics and Genomics | Oncology | Genetics | Pharmacology | Pharmacology and Toxicology | Cell Biology | Studies | Proteins | Clinical trials | Brain cancer | Tumors
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 09/2019, Volume 178, pp. 417 - 432
In novel synthetic 28 4-arylamino-6-fluoro quinazoline derivatives, compound displayed the most remarkable inhibitory activities against tumor cells (IC values... 
Antitumor activity | Mitochondria | Quinazoline | Self-fluorescence | APOPTOSIS | DESIGN | CHEMISTRY, MEDICINAL | MOIETY | TYROSINE KINASE | POTENT EGFR INHIBITORS | CANCER | GROWTH-FACTOR RECEPTOR | ANTICANCER | BIOLOGICAL EVALUATION | ENHANCED ANTIPROLIFERATIVE ACTIVITIES | Cytochrome c | Phosphates | Fluorescence | Analysis
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 10/2018, Volume 17, Issue 10, pp. 2112 - 2122
Journal Article
Nanomedicine: Nanotechnology, Biology, and Medicine, ISSN 1549-9634, 2012, Volume 8, Issue 1, pp. 103 - 111
Journal Article
European Journal of Pharmaceutics and Biopharmaceutics, ISSN 0939-6411, 09/2014, Volume 88, Issue 1, pp. 216 - 225
Hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide. Epirubicin (EPI), an anthracycline derivative, is one of the main line... 
Hepatocellular carcinoma | Asialofetuin | Epirubicin | Cardiotoxicity | Chitosan-PLGA nanoparticles | Tocotrienols | delta-Tocotrienol (PubChem CID: 5282350) | Epirubicin hydrochloride (PubChem CID: 65348) | Poly (d,l-lactic-co-glycolic acid) (PubChem CID: 23111554) | Polyvinyl alcohol (PubChem CID: 11199) | OXIDATIVE STRESS | PANCREATIC-CANCER | IN-VITRO | ENHANCED PERMEABILITY | GAMMA-TOCOTRIENOL | CHITOSAN-BASED FORMULATIONS | PHARMACOLOGY & PHARMACY | MULTIDRUG-RESISTANCE | NF-KAPPA-B | ANTISENSE OLIGONUCLEOTIDES | SUPEROXIDE-DISMUTASE | Nanoparticles - chemistry | Glutathione - metabolism | Humans | Neovascularization, Pathologic | Antibiotics, Antineoplastic - adverse effects | Drug Delivery Systems | Tocotrienols - chemistry | Carcinoma, Hepatocellular - drug therapy | Liver - drug effects | Hepatocytes - drug effects | Superoxide Dismutase - metabolism | Disease Models, Animal | Cell Survival - drug effects | Lactic Acid - chemistry | Liver Neoplasms - drug therapy | Tumor Suppressor Protein p53 - metabolism | Antineoplastic Agents - chemistry | Hep G2 Cells | Animals | Chitosan - chemistry | Antibiotics, Antineoplastic - therapeutic use | Polyglycolic Acid - chemistry | Epirubicin - therapeutic use | Heart - drug effects | Glutathione - chemistry | Mice | Lipid Peroxidation | Apoptosis | Epirubicin - adverse effects | Anthracyclines
Journal Article
by Xie, Y and Sheng, W and Miao, J and Xiang, J and Yang, J
Cancer Gene Therapy, ISSN 0929-1903, 03/2011, Volume 18, Issue 3, pp. 176 - 188
The inhibitor of growth (ING) family proteins have been defined as candidate tumor suppressors. ING4 as a novel member of the ING family has potential... 
ING4 | enhanced antitumor activity | adenoviral vector | cisplatin | hepatocarcinoma | MEDICINE, RESEARCH & EXPERIMENTAL | LIVER-TRANSPLANTATION | CANCER-SPECIFIC ADENOVIRUS | ANGIOGENESIS | TUMOR-SUPPRESSOR GENE | GROWTH 4 | SPLICE VARIANTS | HEPATOCELLULAR-CARCINOMA | INHIBITION | ONCOLOGY | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | CYCLE ALTERATION | GENETICS & HEREDITY | PHD FINGER | Genetic Therapy | Antigens, CD34 - metabolism | Apoptosis - drug effects | Homeodomain Proteins - metabolism | Humans | Gene Expression Regulation, Neoplastic | Neovascularization, Pathologic - pathology | Cisplatin - toxicity | Tumor Suppressor Proteins - genetics | HEK293 Cells | Adenoviridae - genetics | Cell Cycle Proteins - genetics | Female | Antineoplastic Agents - pharmacology | Neovascularization, Pathologic - therapy | Cell Line | Tumor Suppressor Proteins - metabolism | Cell Cycle Proteins - metabolism | Genetic Vectors - metabolism | Cisplatin - pharmacology | Genetic Vectors - genetics | Homeodomain Proteins - genetics | Hep G2 Cells | Xenograft Model Antitumor Assays | Animals | Signal Transduction - drug effects | Mice, Nude | Carcinoma, Hepatocellular - pathology | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Adenoviridae - metabolism | Usage | Care and treatment | Adenoviruses | Physiological aspects | Genetic aspects | Research | Hepatoma | Gene therapy | Cisplatin | Methods | Index Medicus | Original
Journal Article
International Journal of Cancer, ISSN 0020-7136, 02/2015, Volume 136, Issue 4, pp. 945 - 954
Journal Article
Journal Article
by Yoon, K and Kang, HC and Li, L and Cho, H and Park, MK and Lee, E and Bae, YH and Huh, KM
POLYMER CHEMISTRY, ISSN 1759-9954, 2015, Volume 6, Issue 4, pp. 531 - 542
In this study, a series of amphiphilic AB2-type 3-miktoarm copolymers consisting of hydrophilic poly(ethylene glycol) (PEG) as the A arm and hydrophobic... 
NANOPARTICLES | ENHANCED PERMEABILITY | POLYMER SCIENCE | BLOCK-COPOLYMERS | DRUG-DELIVERY | RETENTION | DOXORUBICIN | MICELLES | NANOSTRUCTURES | STAR POLYMERS | PEGYLATION
Journal Article
International Journal of Nanomedicine, ISSN 1176-9114, 08/2016, Volume 11, pp. 3979 - 3991
Oral administration of paclitaxel (PTX), a broad spectrum anticancer agent, is challenged by its low uptake due to its poor bioavailability, efflux through... 
Anticancer nanomedicine | Enhanced permeability and retention (EPR) effect | HUVEC | Antiangiogenic | CT-26 | Oral delivery | VASCULOGENIC MIMICRY | COMPLEX MICELLES | PERMEABILITY | enhanced permeability and retention (EPR) effect | DRUG-DELIVERY | antiangiogenic | DOXORUBICIN | TUMOR | NANOSCIENCE & NANOTECHNOLOGY | BIOAVAILABILITY | CHEMOTHERAPY | anticancer nanomedicine | COLORECTAL-CANCER | oral delivery | PHARMACOLOGY & PHARMACY | LIPOSOMES | Neovascularization, Physiologic - drug effects | Colonic Neoplasms - drug therapy | Humans | Body Weight - drug effects | Microvessels - pathology | Biological Availability | Alanine Transaminase - blood | Polystyrenes - chemistry | Antineoplastic Agents, Phytogenic - administration & dosage | Paclitaxel - toxicity | Micelles | Female | Antineoplastic Agents, Phytogenic - therapeutic use | Paclitaxel - administration & dosage | Disease Models, Animal | Colonic Neoplasms - blood supply | Administration, Oral | Microvessels - drug effects | Maleates - chemistry | Static Electricity | Paclitaxel - therapeutic use | Antineoplastic Agents, Phytogenic - toxicity | Maximum Tolerated Dose | Animals | Colonic Neoplasms - pathology | Cell Line, Tumor | Drug Liberation | ATP Binding Cassette Transporter, Sub-Family B | Mice, Inbred BALB C | Toxicity Tests | Colon cancer | Research | Analysis | Oncology, Experimental | Cancer | Drug delivery systems | Colorectal cancer | FDA approval | Permeability | Bioavailability | Retention | Metabolism | Cancer therapies | Cell adhesion & migration | Biomedical materials | Acids | Mutation | Tumors | paclitaxel | enhanced permeability and retention effect (EPR) | colon cancer | Styrene maleic acid
Journal Article
Journal Article
Journal Article